Myocardial infarction impairs renal function, induces renal interstitial fibrosis, and increases renal KIM-1 expression: Implications for cardiorenal syndrome

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 9, 2012, Pages

  Lekawanvijit, Suree ^a   Kompa, Andrew R ^a,b   Zhang, Yuan ^b   Wang, Bing H ^a   Kelly, Darren J ^b   Krum, Henry ^a  

^a MONASH UNIVERSITY MALAYSIA   (Malaysia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Kidney injury molecule 1; Renal impairment; Smad2 signaling pathway

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; INTERLEUKIN 6; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARDIORENAL SYNDROME; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE DP-DT; HEART PRELOAD; HEART WEIGHT; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY FUNCTION; LYMPHOCYTIC INFILTRATION; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CARDIO-RENAL SYNDROME; CELL ADHESION MOLECULES; DISEASE MODELS, ANIMAL; FIBROSIS; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; INTERLEUKIN-6; KIDNEY; MALE; MYOCARDIAL INFARCTION; RATS; RATS, SPRAGUE-DAWLEY; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84860522968     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00967.2011     Document Type: Article

References (55)

1. Akiyama-Uchida Y, Ashizawa N, Ohtsuru A, Seto S, Tsukazaki T, Kikuchi H, Yamashita S, Yano K. Norepinephrine enhances fibrosis mediated by TGF-beta in cardiac fibroblasts. Hypertension 40: 148-154, 2002.
2. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351: 1285-1295, 2004.
3. Balbay Y, Tikiz H, Baptiste RJ, Ayaz S, Sasmaz H, Korkmaz S. Circulating interleukin-1 beta, interleukin-6, tumor necrosis factor-alpha, and soluble ICAM-1 in patients with chronic stable angina and myocardial infarction. Angiology 52: 109-114, 2001.
4. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 281: F887-F899, 2001.
5. Berger R, Pacher R. The role of the endothelin system in myocardial infarction-new therapeutic targets? Eur Heart J 24: 294-296, 2003.
6. Dargie HJ, McAlpine HM, Morton JJ. Neuroendocrine activation in acute myocardial infarction. J Cardiovasc Pharmacol 9, Suppl 2: S21-24, 1987.
7. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425: 577-584, 2003.
8. Eddy AA. Experimental insights into the tubulointerstitial disease accompanying primary glomerular lesions. J Am Soc Nephrol 5: 1273-1287, 1994.
9. Eddy AA. Molecular basis of renal fibrosis. Pediatr Nephrol 15: 290-301, 2000.
10. Fraccarollo D, Galuppo P, Hildemann S, Christ M, Ertl G, Bauersachs J. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction. J Am Coll Cardiol 42: 1666-1673, 2003.
11. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 58: 88-111, 2008.
12. Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc Res 81: 474-481, 2009.
13. Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J. Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. Cardiovasc Res 57: 749-756, 2003.
14. Gibson CM, Pinto DS, Murphy SA, Morrow DA, Hobbach HP, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 42: 1535-1543, 2003.
15. Goldberg A, Kogan E, Hammerman H, Markiewicz W, Aronson D. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int 76: 900-906, 2009.
16. Goldman S, Raya TE. Rat infarct model of myocardial infarction and heart failure. J Card Fail 1: 169-177, 1995.
17. Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. Cytokine signaling during myocardial infarction: sequential appearance of IL-1β and IL-6. Am J Physiol Regul Integr Comp Physiol 269: R229-R235, 1995.
18. Guo Y, Yuan W, Wang L, Shang M, Peng Y. Parathyroid hormonepotentiated connective tissue growth factor expression in human renal proximal tubular cells through activating the MAPK and NF-κB signalling pathways. Nephrol Dial Transplant 26: 839-847, 2011.
19. Han WK, Bailly V, Abichandani R, Thadhani R, Bonventre JV. Kidney injury molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int 62: 237-244, 2002.
20. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial. Eur Heart J 24: 412-420, 2003.
21. Ichimura T, Bonventre JV, Bailly V, Wei H, Hession CA, Cate RL, Sanicola M. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is upregulated in renal cells after injury. J Biol Chem 273: 4135-4142, 1998.
22. Jerums G, Allen TJ, Cooper ME. Triphasic changes in selectivity with increasing proteinuria in type 1 and type 2 diabetes. Diabet Med 6: 772-779, 1989.
23. Jose P, Skali H, Anavekar N, Tomson C, Krumholz HM, Rouleau JL, Moye L, Pfeffer MA, Solomon SD. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 17: 2886-2891, 2006.
24. Kelly DJ, Wilkinson-Berka JL, Allen TJ, Cooper ME, Skinner SL. A new model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-2)27 rat (TGR). Kidney Int 54: 343-352, 1998.
25. Klopper JF, Hauser W, Atkins HL, Eckelman WC, Richards P. Evaluation of 99m Tc-DTPA for the measurement of glomerular filtration rate. J Nucl Med 13: 107-110, 1972.
26. Kompa AR, Wang BH, Phrommintikul A, Ho PY, Kelly DJ, Behm DJ, Douglas SA, Krum H. Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy. Peptides 31: 1523-1530, 2010.
27. Lachtermacher S, Esporcatte BL, Montalvao F, Costa PC, Rodrigues DC, Belem L, Rabischoffisky A, Faria Neto HC, Vasconcellos R, Iacobas S, Iacobas DA, Dohmann HF, Spray DC, Goldenberg RC, Campos-de-Carvalho AC. Cardiac gene expression and systemic cytokine profile are complementary in a murine model of post-ischemic heart failure. Braz J Med Biol Res 43: 377-389, 2010.
28. Leask A. TGFbeta, cardiac fibroblasts, and the fibrotic response. Cardiovasc Res 74: 207-212, 2007.
29. Li L, Emmett N, Mann D, Zhao X. Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy. Exp Biol Med (Maywood) 235: 383-391.
30. Liao R. Yin and Yang of myocardial transforming growth factor-beta1: timing is everything. Circulation 111: 2416-2417, 2005.
31. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond) 113: 267-278, 2007.
32. Martin FL, Huntley BK, Harders GE, Sandberg SM, Chen HH, Burnett JC Jr. Myocardial infarction mediates renal fibrosis and activates renal molecular remodeling in the absence of heart failure (Abstract). Circulation 116: II-60, 2007.
33. Martin J, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, Krum H, Wilkinson-Berka J, Gilbert RE. Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factorbeta. Cardiovasc Res 65: 694-701, 2005.
34. Massague J, Seoane J, Wotton D. Smad transcription factors. Genes Dev 19: 2783-2810, 2005.
35. McDonald L, Baker C, Bray C, McDonald A, Restieaux N. Plasmacatecholamines after cardiac infarction. Lancet 2: 1021-1023, 1969.
36. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24: 307-315, 2004.
37. Naito K, Anzai T, Yoshikawa T, Anzai A, Kaneko H, Kohno T, Takahashi T, Kawamura A, Ogawa S. Impact of chronic kidney disease on postinfarction inflammation, oxidative stress, and left ventricular remodeling. J Card Fail 14: 831-838, 2008.
38. Nathan CF. Secretory products of macrophages. J Clin Invest 79: 319-326, 1987.
39. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 94: 1543-1553, 2004.
40. Packer M. Why do the kidneys release renin in patients with congestive heart failure? A nephrocentric view of converting-enzyme inhibition. Eur Heart J 11, Suppl D: 44-52, 1990.
41. Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Longterm prognosis of acute kidney injury after acute myocardial infarction. Arch Intern Med 168: 987-995, 2008.
42. Persson H, Andreasson K, Kahan T, Eriksson SV, Tidgren B, Hjemdahl P, Hall C, Erhardt L. Neurohormonal activation in heart failure after acute myocardial infarction treated with beta-receptor antagonists. Eur J Heart Fail 4: 73-82, 2002.
43. Phrommintikul A, Tran L, Kompa A, Wang B, Adrahtas A, Cantwell D, Kelly DJ, Krum H. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am J Physiol Heart Circ Physiol 294: H1804-H1814, 2008.
44. Rached E, Hoffmann D, Blumbach K, Weber K, Dekant W, Mally A. Evaluation of putative biomarkers of nephrotoxicity after exposure to ochratoxin a in vivo and in vitro. Toxicol Sci 103: 371-381, 2008.
45. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, Yoshikawa J. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116-124, 1998.
46. Sigurdsson A, Held P, Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J 126: 1068-1076, 1993.
47. Takeda Y, Nishikimi T, Akimoto K, Matsuoka H, Ishimitsu T. Beneficial effects of a combination of Rho-kinase inhibitor and ACE inhibitor on tubulointerstitial fibrosis induced by unilateral ureteral obstruction. Hypertens Res 33: 965-973.
48. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 334: 1448-1460, 1996.
49. Thompson NL, Bazoberry F, Speir EH, Casscells W, Ferrans VJ, Flanders KC, Kondaiah P, Geiser AG, Sporn MB. Transforming growth factor beta-1 in acute myocardial infarction in rats. Growth Factors 1: 91-99, 1988.
50. Tzanidis A, Lim S, Hannan RD, See F, Ugoni AM, Krum H. Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). J Mol Cell Cardiol 33: 969-981, 2001.
51. van Timmeren MM, van den Heuvel MC, Bailly V, Bakker SJ, van Goor H, Stegeman CA. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212: 209-217, 2007.
52. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, Lee HT. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105: 485-491, 2006.
53. Wolf G. Renal injury due to renin-angiotensin-aldosterone system activation of the transforming growth factor-beta pathway. Kidney Int 70: 1914-1919, 2006.
54. Zion MM, Balkin J, Rosenmann D, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry SPRINT Study Group. Chest 98: 1331-1335, 1990.
55. Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 299: F1203-F1211, 2010.